Acetylated glycosylated threonine derivatives—key intermediates in glycopeptide synthesis 878483-13-7

Glycopeptides, as an important class of biomolecules, play a key role in cell recognition, immune response and disease treatment. Among them, L-Threonine,O-[4,6-di-O-acetyl-2-(acetylamino)-2-deoxy-3-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β- D-glucopyranosyl]-α-D-galactopyranosyl]-N-[(9H-luoren-9-ylmethoxy)carbonyl]-, as a key intermediate in glycopeptide synthesis, is becoming a revolutionary tool in the fields of glycoengineering and drug development. This compound not only embodies the precision design of modern synthetic chemistry, but also provides a solid foundation for the development of glycopeptide drugs.

Chemical Information

Chemical name: L-Threonine, O-[4,6-di-O-acetyl-2-(acetylamino)-2-deoxy-3-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-α-D-galactopyranosyl]-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-

Common name: Acetylated glycosylated threonine Fmoc derivative

Chemical formula: C45H55N3O20

Molecular weight: 957.93 g/mol

CAS number: 878483-13-7

Category: Glycopeptides

Structural features

The structural design of this compound demonstrates the complexity and elegance of glycopeptide chemistry and is unique in that:

Multiple acetylation protecting groups: The hydroxyl and amino groups on the sugar unit are protected by acetyl groups, which not only enhances the stability of the intermediate and prevents unnecessary side reactions during the synthesis process, but also optimizes its solubility and reaction controllability. Acetylation is a commonly used strategy in glycochemistry to simplify purification steps and increase yields.

Precise glycosylation linkage: The molecule contains a disaccharide structure consisting of β-D-glucosamine and α-D-galactosamine linked to the threonine side chain via glycosidic bonds. This specific glycosylation pattern mimics the O-linked glycoforms in native glycoproteins and provides a standard template for studying the impact of glycosylation on biological functions. The stereochemistry of the glycosidic bond is carefully designed to ensure consistency with the native conformation.

Fmoc protecting group: The 9-fluorenylmethoxycarbonyl (Fmoc) protecting group introduced at the N-terminus makes it fully compatible with solid-phase peptide synthesis (SPPS) technology. The Fmoc group can be efficiently removed under mild alkaline conditions, avoiding damage to the side chain sugar structure, thereby supporting the gradual extension of the polypeptide chain, and is suitable for automated synthesis of complex glycopeptides.

Enhanced molecular flexibility: By coupling sugar units to the amino acid backbone, this derivative provides sufficient conformational freedom while maintaining a rigid sugar ring structure, which is helpful for exploring the dynamic behavior of sugar-peptide interactions in biorecognition.

Main applications and advantages

Core building blocks of glycopeptide drug synthesis

In the development of glycopeptide drugs (such as antibiotic vancomycin analogs, anti-tumor vaccines and immunomodulators), this compound serves as a key intermediate and can efficiently introduce pre-assembled disaccharide units. This simplifies the tedious stepwise glycosylation steps in traditional glycopeptide synthesis and significantly improves synthesis efficiency and product purity. Its stable acetylation protection ensures the integrity of the sugar structure during multi-step reactions, reduces the formation of by-products, and lays the foundation for large-scale production.

An important tool for basic research on glycobiology

Glycosylation is a core process of protein post-translational modification, affecting protein folding, stability and cell signaling. This derivative provides a standardized glycosylated amino acid module that can be used for chemoenzymatic synthesis or full chemical synthesis of customized glycopeptides to help analyze the role of glycosylation in disease mechanisms (such as cancer, infectious diseases). For example, by embedding them into peptide sequences, the effect of specific glycoforms on receptor binding affinity can be studied, advancing the development of glycomics.

Precursor molecules for drug development platforms

Based on this intermediate, researchers can construct diverse glycopeptide libraries for high-throughput screening of inhibitors targeting pathogen adhesion, immune checkpoints, or enzyme activity. Its Fmoc protection properties support combinatorial chemistry strategies and accelerate the optimization of lead compounds. In addition, glycopeptide drug candidates can improve pharmacokinetic properties through this building block, such as enhanced serum stability, targeted delivery capabilities, and reduced immunogenicity risks.

Potential applications in diagnostics and vaccine design

Glycopeptides have value in disease biomarker discovery and vaccine design. As a basis for synthetic antigens, this compound can be used to prepare glycopeptide microarrays or coupled carrier proteins to develop diagnostic reagents and vaccines against bacterial, viral or tumor-associated glycoantigens. Its structural homogeneity ensures diagnostic specificity and controllable immunogenicity of the vaccine.

Conclusion

L-Threonine,O-[4,6-di-O-acetyl-2-(acetylamino)-2-deoxy-3-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β- D-glucopyranosyl]-α-D-galactopyranosyl]-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-is not only a synthetic intermediate, but also a bridge between glycoscience and therapeutic applications. From antibiotic resistance response to precision cancer treatment, from immune engineering to regenerative medicine, its modular design injects vitality into innovation in the field of glycopeptides. As the glycopeptide drug market expands, this compound will continue to empower the next generation of biopharmaceutical research and development and open a new era of glycosylation therapy.

The above information is provided by the editor of KASONS and is for scientific research only.